TR201901299T4 - Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri. - Google Patents

Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri. Download PDF

Info

Publication number
TR201901299T4
TR201901299T4 TR2019/01299T TR201901299T TR201901299T4 TR 201901299 T4 TR201901299 T4 TR 201901299T4 TR 2019/01299 T TR2019/01299 T TR 2019/01299T TR 201901299 T TR201901299 T TR 201901299T TR 201901299 T4 TR201901299 T4 TR 201901299T4
Authority
TR
Turkey
Prior art keywords
obese
compounds
morbidly
methods
patient
Prior art date
Application number
TR2019/01299T
Other languages
English (en)
Inventor
Ozcan Umut
Original Assignee
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Ct Corp filed Critical Childrens Medical Ct Corp
Publication of TR201901299T4 publication Critical patent/TR201901299T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Formül I ile tanımlanan bileşikleri veya farmasötik olarak kabul edilebilir bir tuzunu veya ön ilacını, bunları içeren bileşimi içeren zayıflatıcı ajanlar ve bunların kullanım yöntemleri burada tarif edilmiştir. Bazı uygulamalarda bileşik, Withaferin A'dır. Diğer uygulamalarda bileşik, Withaferin A'nın Michael katkı ürünüdür. Bileşimler bir pre-obez, obez veya morbid obez bir hastada kilo kaybının başlatılmasında kullanım için; bir pre-obez, obez veya morbid obez bir hastada vücut yağının azaltılması için; bir pre-obez, obez veya morbid obez bir hastada glukoz homeostazının iyileştirilmesi veya bunların kombinasyonları için uygulanabilir.
TR2019/01299T 2013-11-26 2014-11-25 Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri. TR201901299T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26

Publications (1)

Publication Number Publication Date
TR201901299T4 true TR201901299T4 (tr) 2019-02-21

Family

ID=52134396

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01299T TR201901299T4 (tr) 2013-11-26 2014-11-25 Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.

Country Status (17)

Country Link
US (1) US20160375039A1 (tr)
EP (1) EP3074033B1 (tr)
JP (2) JP6672157B2 (tr)
AU (2) AU2014354831B2 (tr)
CA (1) CA2931826C (tr)
CY (1) CY1122551T1 (tr)
DK (1) DK3074033T3 (tr)
ES (1) ES2709976T3 (tr)
HR (1) HRP20190219T1 (tr)
HU (1) HUE042196T2 (tr)
LT (1) LT3074033T (tr)
PL (1) PL3074033T3 (tr)
PT (1) PT3074033T (tr)
RS (1) RS58422B1 (tr)
SI (1) SI3074033T1 (tr)
TR (1) TR201901299T4 (tr)
WO (1) WO2015081093A1 (tr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
US20210106525A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU531759B2 (en) 1978-04-17 1983-09-08 Ici Ltd. Electrostatic spraying
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
PL324284A1 (en) 1995-06-30 1998-05-11 Lilly Co Eli Methods of treating diabetes
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
ATE455554T1 (de) 1995-11-22 2010-02-15 Amgen Inc Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
WO1997048419A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
EP1001768A1 (en) 1996-08-30 2000-05-24 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
IL129057A0 (en) 1996-09-20 2000-02-17 Hoechst Ag Use of leptin antagonists for treating insulin resistance in type II diabetes
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
EP1835030A1 (en) 1996-12-20 2007-09-19 Amgen, Inc. OB fusion protein compositions and methods
JP4086908B2 (ja) 1997-04-17 2008-05-14 アムジエン・インコーポレーテツド 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
KR20010013414A (ko) 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
CA2337667C (en) 1998-08-10 2008-04-29 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
AU6396999A (en) 1998-10-02 2000-04-26 Amgen, Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
DE60027409T2 (de) 1999-02-12 2007-04-12 Amgen Inc., Thousand Oaks Glykosylierte leptinzusammensetzungen und zugehörige verfahren
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
US20100120747A1 (en) * 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) * 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
CY1122551T1 (el) 2021-01-27
EP3074033B1 (en) 2018-11-07
AU2014354831A1 (en) 2016-06-09
ES2709976T3 (es) 2019-04-22
HUE042196T2 (hu) 2019-06-28
EP3074033A1 (en) 2016-10-05
AU2018200517A1 (en) 2018-02-15
PT3074033T (pt) 2019-02-08
JP6672157B2 (ja) 2020-03-25
SI3074033T1 (sl) 2019-03-29
HRP20190219T1 (hr) 2019-03-22
AU2018200517B2 (en) 2019-12-19
AU2014354831B2 (en) 2017-10-26
DK3074033T3 (en) 2019-02-11
RS58422B1 (sr) 2019-04-30
JP2016537431A (ja) 2016-12-01
US20160375039A1 (en) 2016-12-29
LT3074033T (lt) 2019-02-25
PL3074033T3 (pl) 2019-08-30
WO2015081093A1 (en) 2015-06-04
CA2931826A1 (en) 2015-06-04
CA2931826C (en) 2021-11-16
JP2020059744A (ja) 2020-04-16

Similar Documents

Publication Publication Date Title
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
PH12016502582B1 (en) TrK-INHIBITING COMPOUND
NZ726366A (en) Syk inhibitors
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
BR112015008447A2 (pt) métodos para tratar câncer
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
TR201901299T4 (tr) Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
PH12016502355A1 (en) Pharmaceutical composition
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
EA201391644A1 (ru) Частично насыщенные трициклические соединения и способы их получения и применения
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
MX2012001838A (es) Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
PH12016502353A1 (en) Pharmaceutical composition
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
TW201613577A (en) Pharmaceutical combinations
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
MX2016008102A (es) Composiciones y métodos para tratar la acumulacion de tejido graso.
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)